GSTP1
RASSF2
Urine (%)
Plasma (%)
Urine (%)
Plasma (%)
Positives (%)
Young asymptomatic males
6
20
37
2
Biopsy negative
59
31
82
16
All stages PCa
81
39
59
31
T1 (n = 47 U, 46 P)
83
37
96
35
T2 (n = 28 U, 25 P)
71
32
82
16
T3 (n = 7)
100
71
100
57
T4 (n = 2)
100
50
100
50
Median DNA (range), ng/ml
Young asymptomatic males
0 (0–0.07)
0 (0–0.00a)
0 (0–0.09)
0 (0–0.00a)
Biopsy negative
0.001 (0–0.15)
0 (0–0.02)
0.007 (0–0.70)
0 (0–0.04)
All stages PCa
0.008 (0–91.18)
0 (0–0.27)
0.025 (0–112.45)
0 (0–0.19)
T1 (n = 47 U, 46 P)
0.006 (0–91.80)
0 (0–0.18)
0.024 (0–112.45)
0 (0–0.19)
T2 (n = 28 U, 25 P)
0.008 (0–0.88)
0 (0–0.05)
0.022 (0–0.91)
0 (0–0.00a)
T3 (n = 7)
0.029 (0.001–14.37)
0.001 (0–0.27)
0.042 (0–19.08)
0.0005 (0–0.02)
T4 (n = 2)
n.a. (0.014–0.14))
n.a. (0–0.00a)
n.a. (0.07–0.08)
n.a. (0–0.00a)
HIST1H4K | TFAP2E | |||
---|---|---|---|---|
Urine (%) | Plasma (%) | Urine (%) | Plasma (%) | |
Positives (%) | ||||
Young asymptomatic males | 14 | 8 | 82 | 2 |
Biopsy negative | 84 | 31 | 100 | 16 |
All stages PCa | 92 | 31 | 100 | 18 |
T1 (n = 47 U, 46 P) | 96 | 28 | 100 | 24 |
T2 (n = 28 U, 25 P) | 82 | 28 | 100 | 4 |
T3 (n = 7) | 100 | 71 | 100 | 29 |
T4 (n = 2) | 100 | 0 | 100 | 0 |
Median DNA (range), ng/ml | ||||
Young asymptomatic males | 0 (0–0.02) | 0 (0–0.01) | 0 (0–0.24) | 0.013 (0–0.00a) |
Biopsy negative | 0.004 (0–0.16) | 0 (0–0.00a) | 0.052 (0.001–0.94) | 0 (0–0.00a) |
All stages PCa | 0.008 (0–47.94) | 0 (0–0.18) | 0.096 (0.004–27.80) | 0 (0–0.14) |
T1 (n = 47 U, 46 P) | 0.008 (0–47.94) | 0 (0–0.18) | 0.106 (0.01–27.80) | 0 (0–0.14) |
T2 (n = 28 U, 25 P) | 0.008 (0–0.72) | 0 (0–0.01) | 0.096 (0.01–4.42) | 0 (0–0.00a) |
T3 (n = 7) | 0.024 (0.00–4.04) | 0.007 (0–0.02) | 0.377 (0.01–6.81) | 0 (0–0.01) |
T4 (n = 2) | 0 (0.01–0.06) | 0 | n.a. (0.08–0.09) | 0 |